1. Home
  2. TBPH vs KREF Comparison

TBPH vs KREF Comparison

Compare TBPH & KREF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • KREF
  • Stock Information
  • Founded
  • TBPH 2013
  • KREF 2014
  • Country
  • TBPH United States
  • KREF United States
  • Employees
  • TBPH N/A
  • KREF N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • KREF Real Estate Investment Trusts
  • Sector
  • TBPH Health Care
  • KREF Real Estate
  • Exchange
  • TBPH Nasdaq
  • KREF Nasdaq
  • Market Cap
  • TBPH 536.5M
  • KREF 623.1M
  • IPO Year
  • TBPH N/A
  • KREF 2017
  • Fundamental
  • Price
  • TBPH $11.15
  • KREF $9.00
  • Analyst Decision
  • TBPH Strong Buy
  • KREF Buy
  • Analyst Count
  • TBPH 5
  • KREF 8
  • Target Price
  • TBPH $16.60
  • KREF $12.22
  • AVG Volume (30 Days)
  • TBPH 245.1K
  • KREF 786.6K
  • Earning Date
  • TBPH 08-04-2025
  • KREF 07-21-2025
  • Dividend Yield
  • TBPH N/A
  • KREF 11.11%
  • EPS Growth
  • TBPH N/A
  • KREF N/A
  • EPS
  • TBPH N/A
  • KREF 0.16
  • Revenue
  • TBPH $65,266,000.00
  • KREF $97,478,000.00
  • Revenue This Year
  • TBPH $43.18
  • KREF $31.59
  • Revenue Next Year
  • TBPH N/A
  • KREF $7.29
  • P/E Ratio
  • TBPH N/A
  • KREF $55.34
  • Revenue Growth
  • TBPH 6.11
  • KREF 93.07
  • 52 Week Low
  • TBPH $7.44
  • KREF $8.28
  • 52 Week High
  • TBPH $11.82
  • KREF $12.95
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 62.38
  • KREF 45.98
  • Support Level
  • TBPH $10.87
  • KREF $8.63
  • Resistance Level
  • TBPH $11.44
  • KREF $9.10
  • Average True Range (ATR)
  • TBPH 0.29
  • KREF 0.21
  • MACD
  • TBPH -0.00
  • KREF -0.02
  • Stochastic Oscillator
  • TBPH 71.92
  • KREF 43.53

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About KREF KKR Real Estate Finance Trust Inc.

KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.

Share on Social Networks: